Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 121,292,136
  • Shares Outstanding, K 1,059,320
  • Annual Sales, $ 2,107 M
  • Annual Income, $ -4,265,200 K
  • 36-Month Beta 0.31
  • Price/Sales 5.28
  • Price/Cash Flow 20.60
  • Price/Book 8.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.36
  • Number of Estimates 5
  • High Estimate 1.40
  • Low Estimate 1.32
  • Prior Year 1.14
  • Growth Rate Est. (year over year) +19.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
108.54 +5.34%
on 11/15/18
119.84 -4.59%
on 12/04/18
+1.14 (+1.01%)
since 11/12/18
3-Month
104.17 +9.76%
on 10/25/18
119.84 -4.59%
on 12/04/18
+8.37 (+7.90%)
since 09/12/18
52-Week
73.69 +55.16%
on 02/09/18
119.84 -4.59%
on 12/04/18
+27.63 (+31.86%)
since 12/12/17

Most Recent Stories

More News
HealthVerity Joins Exclusive Group of Leaders as New Member of Hyperledger

Announced today at the Global Forum in Basel, Switzerland, HealthVerity has joined Hyperledger, an open source effort created to advance cross-industry blockchain technologies. Hosted by The Linux Foundation,...

LLY : 114.34 (-0.14%)
AXP : 107.48 (+1.97%)
Global Insulin Delivery Devices Market Outlook to 2024 with Profiles of Novo Nordisk, Sanofi Aventis, Eli Lilly and Company & Merck & Co

The "Global Insulin Delivery Devices Market (By Type - Insulin Pen, Insulin Vial & Syringes and Insulin Pumps; By Region - Europe, North America & Asia Pacific) Market Outlook 2024" report has been...

NVO : 46.01 (+1.79%)
MRK : 78.01 (+1.17%)
LLY : 114.34 (-0.14%)
AC Immune and Lilly Announce License and Collaboration Agreement

--AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approximately CHF1.7 billion in other potential...

ACIU : 11.10 (-3.90%)
LLY : 114.34 (-0.14%)
Lilly and AC Immune Announce License and Collaboration Agreement

-- Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases.

ACIU : 11.10 (-3.90%)
LLY : 114.34 (-0.14%)
Alder BioPharmaceuticals(R) Appoints Carlos Campoy Chief Financial Officer

Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced the appointment of Carlos Campoy...

ALDR : 11.50 (+0.61%)
AGN : 152.27 (+1.72%)
LLY : 114.34 (-0.14%)
Bristol-Myers to Study Opdivo in Combo With Vedanta's VE800

Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.

JNJ : 147.10 (+0.41%)
LLY : 114.34 (-0.14%)
ABBV : 88.60 (+0.49%)
BMY : 53.44 (+1.93%)
The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company

The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company

BLK : 390.07 (+1.14%)
LLY : 114.34 (-0.14%)
ANTM : 278.56 (+0.84%)
CME : 188.57 (-0.50%)
SO : 47.01 (-1.16%)
Pfenex Submits New Drug Application to U.S. FDA Seeking Approval of PF708 for the Treatment of Osteoporosis

Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of PF708 for the treatment of osteoporosis....

PFNX : 4.03 (+5.50%)
LLY : 114.34 (-0.14%)
Mallinckrodt (MNK) to Separate Generics & Branded Businesses

Mallinckrodt (MNK) announces plans to split its generic and branded businesses into two different companies.

MRK : 78.01 (+1.17%)
LLY : 114.34 (-0.14%)
MNK : 20.85 (-0.43%)
BMY : 53.44 (+1.93%)
SmarTrend Watching for Potential Rebound in Shares of Eli Lilly & Co After 1.82% Loss

Eli Lilly & Co (NYSE:LLY) traded in a range yesterday that spanned from a low of $114.24 to a high of $115.99. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $116.22...

LLY : 114.34 (-0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade LLY with:

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

2nd Resistance Point 116.25
1st Resistance Point 115.30
Last Price 114.34
1st Support Level 113.83
2nd Support Level 113.31

See More

52-Week High 119.84
Last Price 114.34
Fibonacci 61.8% 102.21
Fibonacci 50% 96.76
Fibonacci 38.2% 91.32
52-Week Low 73.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar